Article Information
History
- June 23, 2021.
Article Versions
- You are currently viewing Version 1 of this article (June 23, 2021 - 10:36).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Phillip A. Swanson II1,*,
- Marcelino Padilla1,
- Wesley Hoyland1,
- Kelly McGlinchey2,
- Paul A. Fields3,
- Sagida Bibi4,
- Saul N. Faust5,
- Adrian B. McDermott1,
- Teresa Lambe6,†,
- Andrew J. Pollard4,†,
- Nicholas M. Durham7,†,
- Elizabeth J. Kelly8,†,
- Study Group,
- Syed Adlou,
- Parvinder K. Aley,
- Brian Angus,
- Rachel Anslow,
- Philip Baker,
- Himanshu Bansal,
- Amy Beveridge,
- Alice Bridges-Webb,
- Steven Ching,
- Paola Cicconi,
- Elizabeth A. Clutterbuck,
- Andrea M. Collins,
- Thomas C. Darton,
- Tesfaye Demissie,
- Tanya Dinesh,
- Alexander D. Douglas,
- Christopher J. A. Duncan,
- Katie J. Ewer,
- Sally Felle,
- Adam Finn,
- Pedro M. Folegatti,
- Michelle Fuskova,
- Sarah C. Gilbert,
- Anna Goodman,
- Christopher A. Green,
- Elizabeth Harbolick,
- Thomas C. Hart,
- Susana Hayes,
- Adrian V. S. Hill,
- Daniel Jenkin,
- Brett M. Jepson,
- Mwila Kasanyinga,
- Simon Kerridge,
- Vincenzo Libri,
- Patrick J. Lillie,
- Alastair C. McGregor,
- Angela M. Minassian,
- Yama F. Mujadidi,
- Fernanda Pilataxi,
- Emma Plested,
- Samuel Provstgaard-Morys,
- Maheshi Ramasamy,
- Hannah Robinson,
- Katherine Sanders,
- Andrew Smith,
- Matthew D. Snape,
- Rinn Song,
- Rebecca K. Sutherland,
- Emma C. Thomson,
- Mark Toshner,
- David P. J. Turner,
- Merryn Voysey and
- Christopher J. Williams
- 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- 2Discovery, Early Oncology, AstraZeneca, Gaithersburg, MD, USA
- 3Adaptive Biotechnologies, Seattle, WA, USA
- 4Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK
- 5NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
- 6Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 7Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, MD, USA
- 8Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
- ↵*To whom correspondence should be addressed: Phillip A. Swanson II, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA phil.swanson{at}nih.gov and Elizabeth J. Kelly, Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA beth.kelly{at}astrazeneca.com
↵† = These authors contributed equally